Valeant Pharmaceuticals Appoints President of Valeant Pharmaceuticals International

Valeant Pharmaceuticals Appoints President of Valeant Pharmaceuticals
International

ALISO VIEJO, Calif., March 19 /PRNewswire-FirstCall/ -- Valeant
Pharmaceuticals (NYSE: VRX) today announced that it has appointed Dr. Bhaskar
Chaudhuri to the position of President, Valeant Pharmaceuticals International,
effective March 10, 2009. In this role, Dr. Chaudhuri will assume
responsibility for overseeing the Dow Services business, corporate business
development activities, the branded generics operations in Mexico and Poland,
and will be a member of Valeant's Executive Management Team.

About Dr. Bhaskar Chaudhuri
Prior to joining Valeant upon the Company's acquisition of Dow Pharmaceutical
Sciences, Inc. on December 31, 2008, Dr. Chaudhuri served for seven years as
President and Chief Executive Officer and a Member of Dow's Board of
Directors. Before joining Dow, Dr. Chaudhuri served as Executive Vice
President of Scientific Affairs at Bertek Pharmaceuticals, a subsidiary of
Mylan Laboratories, where he oversaw the research and development activities
for its Cardiovascular, Neurology and Dermatology businesses, as well as a
segment of its manufacturing operations.

Prior to his positions at Bertek, Dr. Chaudhuri served as the General Manager
of the Dermatology Division of Mylan Laboratories. Dr. Chaudhuri joined Mylan
through the acquisition of Penederm Inc., where he was the Vice President of
R&D from 1992 to 1998.

Dr. Chaudhuri has over 20 years experience in pharmaceutical management
service, research and development. He holds a Doctorate in Physical Pharmacy,
a Masters of Science in Industrial Pharmacy and a Bachelors of Science in
Pharmacy.

As is the case with other members of Valeant's senior management, Dr.
Chaudhuri's compensation package is directly linked to the performance of
Valeant and is intended to provide a strong and direct link to the company's
future.

About Valeant
Valeant Pharmaceuticals International (NYSE: VRX) is a multinational specialty
pharmaceutical company that develops, manufactures and markets a broad range
of pharmaceutical products primarily in the areas of neurology and
dermatology. More information about Valeant can be found at www.valeant.com.

FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements, including, but not
limited to, statements regarding the future of Valeant's business and
performance. These statements are based upon the current expectations and
beliefs of Valeant's management and are subject to certain risks and
uncertainties that could cause actual results to differ materially from those
described in the forward-looking statements. These risks and uncertainties
include, but are not limited to, risks and uncertainties related to Valeant's
ability to successfully integrate its acquisitions and to realize the benefits
of these acquisitions and management's ability to improve operations, as well
as other risks and uncertainties discussed in the company's filings with the
SEC. The company cautions the reader that these factors are among the factors
that could cause actual results to differ materially from the expectations
described in the forward-looking statements. The company also cautions the
reader that undue reliance should not be placed on any of the forward-looking
statements, which speak only as of the date of this press release. The company
undertakes no responsibility to update any of these forward-looking statements
to reflect events or circumstances after the date of this press release or to
reflect actual outcomes.

Contact:
Laurie W. Little
Valeant Pharmaceuticals
949-461-6002

(Logo: http://www.newscom.com/cgi-bin/prnh/20081125/VALEANTLOGO)

SOURCE Valeant Pharmaceuticals International

Laurie W. Little of Valeant Pharmaceuticals, +1-949-461-6002